The MND Research Blog reports that Cytokinetics Inc. has announced in their official press release published on 21 November 2017, that they will not be continuing work on tirasemtiv after disappointing results in the latest Phase 3 clinical trial. The trial, known under the acronym ‘VITALITY-ALS’, tested whether the drug has a beneficial effect on the breathing function and muscle strength of people with MND.
2017 has seen many community events held across NSW and ACT. Special thanks must go to each and every organiser who gave so generously of their time to raise funds for MND NSW and awareness about MND. Thank you to the following supporters:
A big thank you for the generous support from LJ Hooker Cessnock who held a Charity Golf Day which raised $4,001.50 for MND NSW.
We are very pleased to announce MND NSW was chosen as a recipient for the Westpac Foundation Community Grants. This grant funding was used to provide our recent Link & Learn 2 day residential program for Carers in Cowra. Thank you Westpac Foundation for supporting this important educational initiative for Carers.
Thank you to the Hub Advisory Group in Newcastle for this wonderful fundraiser, and for the donation from the event of $1,556 to MND NSW. Special thanks to Shanelle Kidd from the Hub Advisory Group who coordinated the event.
